These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. van der Molen AJ. J Med Imaging Radiat Oncol; 2008 Aug 01; 52(4):339-50. PubMed ID: 18811757 [Abstract] [Full Text] [Related]
8. [Nephrogenic systemic fibrosis]. Breitschaft A, Stahlmann R. Med Monatsschr Pharm; 2009 Oct 01; 32(10):377-82. PubMed ID: 19886227 [Abstract] [Full Text] [Related]
9. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Kay J. Ann Rheum Dis; 2008 Dec 01; 67 Suppl 3():iii66-9. PubMed ID: 19022818 [Abstract] [Full Text] [Related]
10. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis? Boyd AS, Sanyal S, Abraham JL. J Am Acad Dermatol; 2010 Feb 01; 62(2):337-42. PubMed ID: 19939504 [Abstract] [Full Text] [Related]
11. Nephrogenic systemic fibrosis: a review of the new conundrum. Goenka AH, Das CJ, Sharma R. Natl Med J India; 2009 Feb 01; 22(6):302-6. PubMed ID: 20384019 [Abstract] [Full Text] [Related]
12. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency. Chewning RH, Murphy KJ. J Vasc Interv Radiol; 2007 Mar 01; 18(3):331-3. PubMed ID: 17377176 [Abstract] [Full Text] [Related]
13. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. J Am Coll Cardiol; 2009 May 05; 53(18):1621-8. PubMed ID: 19406336 [Abstract] [Full Text] [Related]
14. Nephrogenic systemic fibrosis: a sufficient reason to avoid gadolinium-based contrast in all patients with renal impairment? Willicombe M, Cunningham J. Semin Dial; 2008 May 05; 21(2):140-1. PubMed ID: 18226007 [Abstract] [Full Text] [Related]
15. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function? Lind Ramskov K, Thomsen HS. Acta Radiol; 2009 Nov 05; 50(9):965-7. PubMed ID: 19863403 [No Abstract] [Full Text] [Related]
16. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Peak AS, Sheller A. Ann Pharmacother; 2007 Sep 05; 41(9):1481-5. PubMed ID: 17684032 [Abstract] [Full Text] [Related]
17. Nephrogenic systemic fibrosis and management of high-risk patients. Altun E, Semelka RC, Cakit C. Acad Radiol; 2009 Jul 05; 16(7):897-905. PubMed ID: 19375360 [Abstract] [Full Text] [Related]
18. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. Stratta P, Canavese C, Quaglia M, Fenoglio R. Rheumatology (Oxford); 2010 Apr 05; 49(4):821-3. PubMed ID: 20032228 [No Abstract] [Full Text] [Related]
20. Current status of gadolinium toxicity in patients with kidney disease. Perazella MA. Clin J Am Soc Nephrol; 2009 Feb 05; 4(2):461-9. PubMed ID: 19201920 [Abstract] [Full Text] [Related] Page: [Next] [New Search]